(Q35069358)

6 August 2017

1 reference

title

Bone metastases in breast cancer (English)

1 reference

6 August 2017

Allan Lipton

1

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Current Treatment Options in Oncology

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

151-158

1 reference

Skeletal complications of malignancy

6 August 2017

cites work

1 reference

12 December 2020

Bisphosphonates: mechanisms of action

1 reference

12 December 2020

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

12 December 2020

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Therapy of metastatic bone pain

1 reference

12 December 2020

A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease

1 reference

12 December 2020

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

1 reference

12 December 2020

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

12 December 2020

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

12 December 2020

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

12 December 2020

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

12 December 2020

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

12 December 2020

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

1 reference

12 December 2020

Novel approaches to the management of bone metastases in patients with breast cancer

1 reference

12 December 2020

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

12 December 2020

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Malignant bone pain: pathophysiology and treatment

1 reference

12 December 2020

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Cancer statistics, 2001

1 reference

12 December 2020

10.1007/S11864-003-0016-9

Identifiers

DOI

1 reference

6 August 2017

1 reference